A randomized controlled phase I/II clinical study investigating the combination of tremelimumab and durvalumab in unresectable HCC patients demonstrated a correlation between early CD8+ T cell expansion and tumor response in each group [12], further emphasizing the significant impact of the immune microenvironment on immunotherapy. The gene discussed is CD8A; the disease is neoplasm.